Skip to content


  • Research
  • Open Access

Sociodemographic characteristics of patients with children in a methadone maintenance program: a cross-sectional study

Harm Reduction Journal201916:13

  • Received: 20 November 2018
  • Accepted: 30 January 2019
  • Published:



Ever-increasing numbers of opioid use disorder (OUD) in Canada has created the recent opioid crisis. One common treatment for OUD is methadone maintenance treatment (MMT). Various factors, including being a parent which entails specific stressors, may increase susceptibility to negative treatment outcomes. This study aims to investigate differences between OUD patients with and without children in socio-demographic and clinical outcomes.


Data for this study are part of a larger program. All participants are 18+ years old with OUD, provided consent, and receiving MMT. We performed a multivariable logistic regression to examine the differences between participants’ parental status, sociodemographic variables, and clinical parameters including MMT outcomes. We performed subgroup analyses on individuals with children younger than 18.


A total of 1099 participants were included, with 64% having children. Participants with children were older (OR 1.06, 95% CI 1.04, 1.08), more likely to be female (OR 2.39, 95% CI 1.75, 3.27), living with a partner (OR 1.75, 95% CI 1.27, 2.41), first exposed to opioids through a prescription (OR 1.517, 95% CI 1.13, 2.04) and had lower levels of education (OR 1.86, 95% CI 1.20, 2.87). There was no significant difference in illicit opioid use patterns between groups. Same results held true in the subgroup analyses based on the age of the children except for participant age.


Our results demonstrate social and demographic differences between parents and non-parents receiving MMT. These differences highlight the need to understand necessary additional support for parents such as child support and other necessary therapies.


  • Cross-sectional
  • Methadone
  • MMT
  • Opioid
  • Behaviors
  • Parental


Prescription opioids (PO) are medications used for treating illnesses including chronic pain and opioid use disorder (OUD) [1]. From 2000 to 2004, the prevalence of Canadian opioid users increased steadily, and in 2013, about 5.9% of the population reported misusing PO [2, 3]. To combat OUD, methadone maintenance treatment (MMT) is commonly used as an opioid substitution therapy due to its availability, government subsidization, and higher efficacy compared to abstinence or solely psychosocial treatment [4, 5]. In Ontario alone, over 50,000 adults were enrolled in MMT in 2013, making MMT the most commonly used opioid substitution therapy [3]. Binding of methadone to receptors significantly decreases withdrawal symptoms and cravings for other opioids by acting as a long-term agonist to these receptors and as an antagonist to the N-methyl-d-aspartate neural receptors [1, 6]. The effects of methadone prevent the user from experiencing the euphoria associated with stronger illicit opioids, decreasing further use [1, 6].

Despite MMT’s effectiveness, studies have shown a 30 to 70% rate of relapse in MMT patients with little research investigating factors explaining such high rates [7, 8]. We speculate this may be because patients on MMT often have a higher number of psychosocial comorbidities that can impact their success in MMT [9]. In addition, many randomized controlled trials that tested the effectiveness of opioid substitution therapies including methadone excluded patients with comorbid disorders leading to various rates of response compared to other types of study designs such as observational studies [10]. Despite studies investigating the efficacy of MMT in the general population [11, 12], there has also been a limited number of studies exploring the influence of parental responsibilities on MMT outcomes.

Undoubtedly, parents are one group of patients with unique social circumstances that may influence their treatment needs or outcomes. Factors include being a parent which comes with stressors and obligations unique to their life that may increase susceptibility to various negative health behaviors. Such stressors may include providing children with the necessities of life, paying larger bills, physical obligations of child care, and higher living expenses. These may result in parents having to work longer hours, being more distressed, and relieving stress with drugs. Although previous studies have examined the role of parental responsibilities on illicit drug use broadly [13, 14] as well as the quality of parenting in MMT patients [15, 16], to our knowledge, no study has explored social demographic variables specifically within the parenting population.

Parents have the responsibility of ensuring the well-being of the child, which comes with numerous daily tasks and considerations. This makes them a unique population within MMT population, thus requiring special considerations of their social demographic situation. Parental responsibilities, such as supervising their child’s behavior, have been reported to be a source of stress for parents [17]. Although physiological and psychological stress have been reported to influence MMT outcomes negatively [18], parents also have been shown to have intrinsic motivation to ensure their child’s safety and wellbeing [19]. Concern over their child’s wellbeing has been shown to be a motivating factor for parents to enter treatment [20]. However, one factor that may discourage parents from entering treatment is avoiding separation from their child due to suspected lack of competency in their child caring duties [21]. Therefore, parents without stable incomes and family support might be more inclined to use other substances or relapse back into illicit opioid use to relieve their overwhelming stress from these responsibilities.

Research has shown conflicting evidence on parental quality as well as addiction treatment outcomes in this population [13, 22, 23]. Studies have found that bearing child care responsibilities negatively affected various treatment outcomes [13]. Some outcomes discussed in the literature include addiction severities as well as psychiatric symptoms [9, 22]. However, studies have found that parents with the community and social support were able to increase MMT adherence and long-term benefits, while lowering the rate of polysubstance use and addiction severities [14, 2326]. It is important to highlight, however, that these studies lacked specificity to an opioid-using or MMT population. Therefore, it is crucial to explore the current social demographic circumstances of the MMT population to gain a comprehensive understanding of their circumstance.

Current literature supports the notion that additional support from various agencies may further motivate parents to adhere to treatment [14, 2326]. This assistance may be in the form of familial support, social services, and additional treatment for their comorbidities, among others [14, 2326]. Further investigating the differences between the two populations may elucidate specific needs within this population not known prior. This may benefit clinicians to better evaluate treatment plans, as well as provide evidence for program designers to ensure MMT programs meet the needs of this patient population. The present cross-sectional study aims to compare social and demographic differences between parents and non-parents with opioid use disorder to further understand patient needs in order to better tailor treatment for them.

The present study’s objectives are as follows:
  1. 1)

    Determine the social and demographic differences between participants with children compared to those without children currently on MMT.

  2. 2)

    Determine the social and demographic differences between participants with children under the age of 18 compared to those without children currently on MMT.



In this study, data were retrieved from an ongoing prospective study, the Genetics of Opioid Research (GENOA) research program, conducted in collaboration with the Population Genomics Program at McMaster University and Canadian Addiction Treatment Centres (CATC) across Ontario. Participants were required to be 18 years of age or older, currently receiving MMT for OUD, provided information regarding parental status, and provided a written informed consent. A detailed description of the GENOA protocol can be found elsewhere [27]. The exclusion criteria for participants included the inability to communicate in English (Fig. 1). We excluded participants from this study with missing data regarding parental status. None of the study participants had missing urine toxicology screens.
Fig. 1
Fig. 1

Participant flow diagram

Data were collected via baseline questionnaires administered to patients from June 2013 to October 2016. Case report forms were used to collect demographic information including parental status, age, sex, duration of opioid use, onset of methadone treatment, age of youngest child, and other substance use in the last month. Methadone dose was self-reported during the baseline interview and was further verified by checking the medical records as per the study procedures and participants’ consent to check the medical records. Although there was no exclusion criterion for the duration on methadone, for example, to reach a stable dose, the average duration in months was 47 months for participants on MMT included in our analysis. Substance use was self-reported using the Maudsley Addiction Profile instrument which has been described previously [28]. The current study extracted data from 1099 participants who completed the baseline screening questionnaires. Parental status was collected from the baseline questionnaire. Specifically, we asked participants the number of children they had, and the ages of the youngest and oldest children.

Participants were followed up for 3 months with weekly or bi-weekly urine drug screens for illicit opioid use. We define treatment outcomes as illicit opioid use measured by any positive opioid urine screens during the 3-month period of the study. Patients with at least one positive opioid urine screen (excluding methadone) were coded positive in illicit opioid use, while patients with no positive opioid urine screens were coded as negative.

Statistical analysis

All statistical analyses were completed using SPSS 23.0 software. For baseline characteristics, means and standard deviations were reported for continuous variables and percentages were reported for dichotomous variables. Continuous variables include age, amount of the last dose, and length of MMT treatment. Dichotomous variables include sex and parental status. Participants with missing values for either their parental status or positive opioid urine screens were excluded from this analysis, resulting in a final model with 1032 participants. Using the rule of 10 events per predictor, with a power of 80%, and alpha of 5%, our study is sufficiently powered to answer our primary question with 12 predictor variables in the main model [29].

A multivariable logistic regression analysis was used to determine the association between having children and varying social factors. We coded parental status, illicit opioid use, employment status, smoking status, and marital status dichotomously. Parental status was coded as either having children or not having children. Illicit opioid use was coded as having used any illicit opioids or having not used any illicit opioids at baseline. Employment status was coded as being currently employed in the last 30 days, or not employed in the last 30 days. Smoking status was coded as current smoker versus former smoker/having never smoked. Marital status was coded as being married, in common law relationships or living with a partner, or divorced, separated, or never married.

We performed a sub-group analysis in participants with children under 18 years of age to test whether parents of younger children have differing social situations. We coded all variables identical to the main regression. We then ran a multivariable logistic regression examining the same factors as the first regression.

Using the variance inflation factor (VIF), we assessed for collinearity and variables with VIF > 10 were subsequently excluded from all analyses. We reported adjusted odds ratio (aOR), 95% confidence intervals (CI), and p values. A two-sided p value of 0.05 or less was considered significant.

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used to ensure standardized reporting in this study [30].


Baseline characteristics

Baseline characteristics are displayed in Table 1. Approximately 64.3% of participants indicated that they had children, with approximately 67.8% of the parenting population with children below the age of 18. The mean age of the participants with children was 41.2 (SD 10.6) years, only 2.1 years older than the average age of participants without children (SD 10.5). Participants with children tended to have less years of education (47.2% of participants with children completed high school vs. 54.8% of participants without children completed high school), more likely to be unemployed (69.7 vs. 59.6%), were currently with a partner (36.1 vs. 24.3%), and first introduced to opioids through a physician prescription (54.6 vs 35.7%). Participants with children also had a longer MMT treatment duration (mean: 51.9 months, SD: 51.6) compared to participants without children (mean: 39.4, SD: 41.6).
Table 1

Patient demographics


Have children (n = 707)

No children (n = 392)

P value

Sex, n (%)


341 (48.2)

259 (66.1)

< 0.0001

Age (years), mean (SD)

41.2 (10.6)

39.1 (10.5)


Highest level of education, n (%)

 Grade 8 and below

175 (24.8)

64 (16.5)


 Grades 9–12

332 (47.2)

213 (54.8)


 College/university, trade school, masters/PhD

196 (27.7)

112 (28.6)


Employment status, n (%)

 Currently employed

214 (30.3)

158 (40.4)


Marital status, n (%)

 Married/common law/living with partner

255 (36.1)

95 (24.3)

< 0.0001

Source of first opioid exposure, n (%)

 Prescribed by physician

386 (54.6)

140 (35.7)

< 0.0001

Smoking status, n (%)

 Current smoker

597 (84.6)

335 (85.4)


Self-reported substance use in the past 30 days, n (%)*


272 (38.4)

179 (45.7)



71 (10.0)

51 (7.2)



78 (11.0)

61 (15.6)



117 (16.5)

84 (21.4)



45 (6.4)

27 (6.9)


 Crack cocaine

81 (11.5)

42 (10.7)



344 (48.6)

235 (59.9)


 Illicit methadone

12 (1.7)

3 (0.8)


 Other drugs**

361 (51.1)

216 (55.1)


Methadone dose (mg/day), mean (SD)

76.0 (46.3)

71.0 (42.9)


Length of current treatment (months), mean (SD)

51.9 (51.6)

39.4 (41.6)

< 0.0001

Age of first opioid use, mean (SD)

26.6 (9.1)

22.8 (7.6)

< 0.0001

Illicit opioid use through urine screens, n (%)

 At least 1 positive urine screen during 3 month study period

395 (55.9)

214 (54.6)


*Some people use more than 1 substance at once so the values of self-reported substance use might not add up to 100% in each row

**Other drugs used by participants include ketamine, Percocet, diluadid, oxycontin, fentanyl, oxycodeine, hydromorphone, morphine, acetaminophen, crystal meth, gabapentin, MDMA, OxyNeo, Ritalin, poppy seed opium, hashish, illicit Suboxone, and codeine

Primary logistic regression

As seen in Table 2, we ran a multivariable logistic regression comparing participants with children and participants without children. Parents were shown to be more likely to be older (aOR for each additional year in age: 1.058, 95% CI 1.039, 1.078, p < 0.0001), more likely to be female (aOR 2.394, 95% CI 1.753, 3.268, p < 0.0001), had an education level of grade 8 (equivalent to 8–10 years of schooling) or below (aOR 1.856, 95% CI 1.199, 2.872, p = 0.005), more likely to be married or in a common law relationship, or living with a partner (aOR 1.750, 95% CI 1.273, 2.406, p < 0.0001), and more likely to have first been exposed to opioids through a physician prescription (aOR 1.517, 95% CI 1.129, 2.038, p = 0.006).
Table 2

Primary logistic regression comparing sociodemographic outcomes between participants without children and participants with children on MMT



95% CI

P value


Lower bounds

Upper bounds


Sex (male)




< 0.0001

Age (years)




< 0.0001

Highest level of education

 Grade 8 and below





 Grades 9–12





 College/university, trade school, or masters/PhD





Employment status





Marital status

 Married/common law/living with partner




< 0.0001

Source of first opioid exposure

 Physician prescribed





Smoking status

 Current smoker





Self-reported substance use in the past 30 days


























 Crack cocaine










 Illicit methadone





 Other drug*





Methadone dose (mg/day)





Length of current treatment (months)





Age of first opioid use





Illicit opioid use by urine screen

At least 1 positive urine screen during 3-month study period





aOR adjusted odds ratio, CI confidence intervals, parental status having one or more children, reference group is being a parent, substance use is not an indication of substance use disorder

*Other drugs used by participants include ketamine, Percocet, diluadid, oxycontin, fentanyl, oxycodeine, hydromorphone, morphine, acetaminophen, crystal meth, gabapentin, MDMA, OxyNeo, Ritalin, poppy seed opium, hashish, illicit Suboxone, and codeine

Subgroup 1: Parents with children at or below 18 years of age

From our total sample of 1032, 446 participants had children younger or at the age of 18. We ran a multivariable logistic regression adjusting for duration of MMT and methadone dose. Results showed that parents with children under the age of 18 were much more likely to be female (aOR 2.201, 95% CI 1.601, 3.025, p < 0.0001), married or in a common law relationship or living with a partner (aOR 1.826, 95% CI 1.317, 2.533, p < 0.0001), have an education level below grade 8 which is equivalent to 8–10 years of schooling (aOR 1.805, 95% CI 1.137, 2.866, p = 0.013), more likely to have first been exposed to opioids through a physician prescription (aOR 1.540, 95% CI 1.132, 2.094, p = 0.006) and likely to be older when they first started opioids (aOR 1.028, 95% CI 1.003, 1.053, p = 0.029) (Table 3).
Table 3

Subgroup of parents with children under 18 compared to the population without children



95% CI

P value


Lower bounds

Upper bounds


Sex (male)




< 0.0001

Age (years)





Highest level of education

 Grade 8 and below





 Grades 9–12





 College/university, trade school, or masters/PhD





Employment status





Marital status

 Married/common law/living with partner




< 0.0001

Source of first opioid exposure

 Physician prescribed





Smoking status

 Current smoker





Self-reported substance use in the past 30 days


























 Crack cocaine










 Illicit methadone





 Other drug*





Methadone dose (mg/day)





Length of current treatment (months)





Age of first opioid use





Illicit opioid use by urine screens

At least 1 positive urine screen during 3 month study period





Included in analysis: 838

aOR adjusted odds ratio, CI confidence intervals, parental status: having one or more children, reference group is being a parent, substance use is not an indication of substance use disorder

*Other drugs used by participants include ketamine, Percocet, diluadid, oxycontin, fentanyl, oxycodeine, hydromorphone, morphine, acetaminophen, crystal meth, gabapentin, MDMA, OxyNeo, Ritalin, poppy seed opium, Hashish, illicit Suboxone, and codeine


The present study suggests differing social and demographic circumstances between the parenting population and the non-parenting population on MMT. Parental status does not influence MMT outcomes, contrary to results from previous studies [13, 31, 32]. In our study, we did not find a statistically significant difference in illicit opioid screens, length of treatment, nor average methadone dose between parents and non-parents. We found age, sex, education, marital status, and physician prescription as first exposure to opioids to be statistically significant in both the main regression and the subgroup analysis. We also found the age of first opioid exposure to be statistically significant in our subgroup analysis. There are a variety of factors that may result in this population being more likely to be first exposed through a physician prescription, such as persistent pain after labor and delivery [33]. These results suggest that individuals with children are demographically different and more likely to receive opioids through a prescription; therefore, they may have different risk factors, such as increased parenting responsibility that can increase daily stress levels or physical stress unique to parents that can impact their likelihood of opioid use disorder requiring special attention from health care providers. However, it must be recognized that this study cannot provide conclusive evidence that having children is a risk factor for opioid use disorder and can only highlight demographic differences in first exposure to opioids.

There has been a limited number of studies exploring the parenting population in MMT specifically. Although previous studies have examined the role of parental responsibilities on illicit drug outcomes [13, 24, 26] as well as exploring the quality of parenting in MMT patients [15] to our knowledge, this is the largest cohort study done investigating population differences between parents and non-parents within a Canadian context. As well, there are methodological differences between previous studies and ours that should be considered. A similar study investigated the influence of parental responsibilities in substance use treatment for residential programs and MMT outcomes and found a general negative association between parental status and various treatment outcomes [13]. However, they do not account for important confounding variables such as the length of the treatment duration, and the dose of methadone provided, both of which have both been found to be important factors in the success of treatment previously [16]. Other studies examined substance use among young parents such as alcohol abuse and patterns of their experiences with child welfare services [24, 26]. Although these studies highlight important considerations in parents with substance use disorder, they lack the comparison between the two patient populations (i.e., patients with children and patients without children) and other social factors that play a role in risk factors for substance use.

In our study, we have shown that parents differ in various sociodemographic categories that may affect their susceptibility to substance use disorder, quality of life, and future treatment outcomes or prognosis. However, there is uncertainty as to whether parents with differing child care responsibilities may present differing vulnerabilities to various risk factors compared to parents without any child care responsibilities. Patients with children on MMT have traditionally been shown to be less involved in parenting responsibilities [34, 35]. Specifically, Suchman and Luthar (2000) reported that mothers with substance use disorders with children under 16 years of age had lower parental involvement in child-caring activities compared to mothers without substance use disorders [34]. Mothers on MMT with children in child care services had lower methadone dose intakes compared to controls, which was not supported by our results [3537]. Likewise, research has also shown that women with parenting responsibilities involved in treatment have more psychiatric symptoms than those without parenting responsibilities [34]. This highlights the need to further examine and evaluate treatment needs for those with children. With high rates of physician prescription opioids in Ontario [38], it is unsurprising that patients with children are significantly more likely to be first exposed to opioids through physician prescriptions than those without children. With the negative outcomes of OUD, and its’ impact on parenting quality, clinicians should be more aware of the potential dangers of prescribing opioids without careful management. As well, chances of obtaining OUD and its’ potential negative impact on parenting abilities should be highlighted on guidelines as an essential point of discussion with patients during informed consent.

In this study, we found that patients with children are more likely to be women compared to patients without children; however, this population may not represent all fathers with OUD because fathers on MMT may be overlooked in treatment. The literature has shown that fathers are more likely to be using opioids at the time of their child’s birth, less likely to be employed, and have relatively poorer vocational status [39, 40]. As well, fathers with OUD are found to be less likely to be the legal guardian of their child, to be living in the same household as the child, and providing financial support [39]. This may explain why we observed higher numbers of females with children in this study.

Strengths and limitations

Our study has a number of strengths. Previous research fails to take into account important confounding factors such as the length of treatment as well as participant’s methadone dose into their analysis [39]. As well, they only conducted a univariate analysis and potentially further subjecting their results to a risk of confounding factors [39, 41]. Our study is unique in that we investigated social demographic differences between the parenting population, examining a wide array of factors that may be associated with a risk of opioid use disorder. In addition, our larger sample is more representative of the OUD population compared to smaller studies that may be at a higher risk of a type I error. With a large sample size, we are more confident in addressing our research question. Furthermore, our data were collected from a heterogeneous sample from various socioeconomic environments. This increases the generalizability of our findings to the general population in Southern Ontario. Lastly, we measure illicit opioid use through urine screens as opposed to self-reports, thus minimizing chances of misclassification bias in our study compared to previous studies that used self-reported illicit opioid use [4244].

There are limitations of our study that should be mentioned. Our study is a cross-sectional design. Therefore, it is not possible to evaluate causation of parental status on any of the sociodemographic variables or treatment outcomes assessed. Second, we did not characterize the extent of the parental responsibilities in participants with children. We recognize that many parents with children in MMT may not be living with their children, and thus, do not carry any added parental responsibilities. Also, we did not measure the amount of support they were receiving, and whether it was spousal, social, or familial support. Furthermore, our recruitment process is through a volunteer basis. Therefore, our sample may be subjected to volunteer bias. Finally, our study may not be generalizable to populations in other provinces or countries, as we only extracted data from participants who attended MMT clinics in Southern Ontario.

Despite our limitations, our study highlights the social demographic differences between well-characterized parents on MMT. These differences may be used by services to improve their assessment and support of patients with children.


The present study explores the social demographic differences between the parenting population and the non-parenting population in MMT, something that is noticeably absent in the literature. Our findings indicate that parents tend to be different than their counterpart in sex, education level, employment status, more likely to be physician prescribed, and started using opioids at an older age. We also found that parents with younger children have similar social and demographic situations compared to all parents. Future research should focus on the relationship between risk factors for OUD and the extent of child care responsibilities for the MMT population. As a society, it is imperative that we generate an environment that is conducive for the healthy development of children. We hope that our findings will support researchers in the further development of MMT programs and encourage further research within this population.



Canadian Addiction Treatment Centres


Genetics of Opioid Research


Methadone maintenance treatment


Opioid use disorder


Prescription opioids



The authors would like to thank Jackie Hudson for all her contributions to the GENOA project. We would also like to thank all the CATC staff and management for their collaboration in this project, as well as the GENOA team members for their expertise, contributions, and time. Lastly, we would like to thank the study participants who volunteered their time and data. Without their contributions and willingness to participate, this project would not have been possible.


This work was supported by research grants from the Canadian Institute for Health Research (CIHR), Ottawa, ON, Canada, the Hamilton Academic Health Sciences Organization, Hamilton, ON, Canada, The Chanchlani Research Centre at the Population Genomics Program, Hamilton, ON, Canada, and the Peter Boris Centre for Addictions Research, Hamilton, ON, Canada. The funding bodies do not have any role in the design of this study, data analysis, or publication of these results.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

CL and ZS synthesized the research question. CL, NS, LZ, MB, LT, and ZS were responsible for the research methodology. NS, LZ, MB, HS, IS, NM, SL, JH, and ZS were responsible for data collection. CL was responsible for the first draft of the written report. All authors edited and approved the final draft of the report.

Ethics approval and consent to participate

GENOA has received research ethics approval from the Hamilton Integrated Research Ethics Board. All participants were consented in-person with research personnel to participate in the study.

Consent for publication

Participants consented to the use of their data for research publications.

Competing interests

The authors declare they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Bachelor of Health Sciences Program, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Medical Sciences Graduate Program, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
MiNDS Graduate Program, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Arts and Science Program, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Department of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Hamilton Health Sciences, 237 Barton St. E., Hamilton, Ontario, L8L 2X2, Canada
Michael G. DeGroote School of Medicine, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Peter Boris Centre for Addictions Research, St Joseph’s Healthcare Hamilton, 100th West 5th St., Hamilton, Ontario, L8N 3K7, Canada
Populaton Genomics Program, Chanchlani Research Centre, McMaster University, 1280 Main St. W., Hamilton, Ontario, L8S 4L8, Canada
Mood Disorders Program, St. Joseph’s Healthcare, 100 West 5th St., Hamilton, Ontario, L8N 3K7, Canada


  1. Chahl LA. Experimental and clinical pharmacology: opioids - mechanisms of action. Aust Prescr. 1996;19:63–5 ArticleGoogle Scholar
  2. Sproule B, Brands B, Li S, Catz-Biro L. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician. 2009;55:68–9 69.e1–5.PubMedPubMed CentralGoogle Scholar
  3. Fischer B, Ialomiteanu A, Boak A, Adlaf E, Rehm J, Mann RE. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada. Drug Alcohol Rev. 2013;32:276–87 ArticleGoogle Scholar
  4. CAMH: Methadone [WWW Document], 2012. URL Accessed 25 Aug 17.
  5. Padaiga Z, Subata E, Vanagas G. Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania. Medicina (Kaunas). 2007;43:235–41.View ArticleGoogle Scholar
  6. Boothby LA, Doering PL. Buprenorphine for the treatment of opioid dependence. Am J Heal Pharm. 2007;64:266-72.Google Scholar
  7. Zhou K, Zhuang G. Retention in methadone maintenance treatment in mainland China, 2004–2012: a literature review. Addict Behav. 2014;39:22–9 ArticleGoogle Scholar
  8. Kellogg S, Melia D, Khuri E, Lin A, Ho A, Kreek MJ. Adolescent and young adult heroin patients. J Addict Dis. 2006;25:15–25 ArticleGoogle Scholar
  9. Carpentier PJ, Krabbe PFM, van Gogh MT, Knapen LJM, Buitelaar JK, de Jong CAJ. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009;18:470–80 ArticleGoogle Scholar
  10. Dennis BB, Roshanov PS, Naji L, Bawor M, Paul J, Plater C, et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials 2015 Dec 21 [cited 2019 Jan 28];16(1):475. Available from:
  11. Szapocznik J, Ladner R. Factors related to successful retention in methadone maintenance: a review. Int J Addict. 1977;12:1067–85 ArticleGoogle Scholar
  12. Babst DV, Chambers CD, Warner A. Patient characteristics associated with retention in a methadone maintenance program. Br J Addict Alcohol Other Drugs. 1971;66:195–204.View ArticleGoogle Scholar
  13. Stewart D, Gossop M, Trakada K. Drug dependent parents: childcare responsibilities, involvement with treatment services, and treatment outcomes. Addict Behav. 2007;32:1657–68 ArticleGoogle Scholar
  14. Hans SL, Bernstein VJ, Henson LG. The role of psychopathology in the parenting of drug-dependent women. Dev Psychopathol. 1999;11:957–77.View ArticleGoogle Scholar
  15. Suchman NE, Rounsaville B, DeCoste C, Luthar S. Parental control, parental warmth, and psychosocial adjustment in a sample of substance-abusing mothers and their school-aged and adolescent children. J Subst Abus Treat. 2007;32:1–10 ArticleGoogle Scholar
  16. Kamal F, Flavin S, Campbell F, Behan C, Fagan J, Smyth R. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J. 2007;100:393–7.PubMedGoogle Scholar
  17. Hildingsson I, Thomas J. Parental stress in mothers and fathers one year after birth. J Reprod Infant Psychol. 2014;32:41–56 ArticleGoogle Scholar
  18. Jaremko KM, Sterling RC, Van Bockstaele EJ. Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance. J Subst Abus Treat. 2015;48:117–27 ArticleGoogle Scholar
  19. Rilling JK, Young LJ. The biology of mammalian parenting and its effect on offspring social development. Science. 2014;345:771-6.Google Scholar
  20. Swift W, Copeland J, Hall W. Characteristics of women with alcohol and other drug problems: findings of an Australian national survey. Addiction. 1996;91:1141–50.View ArticleGoogle Scholar
  21. Lundgren LM, Schilling RF, Fitzgerald T, Davis K, Amodeo M. Parental status of women injection drug users and entry to methadone maintenance. Subst Use Misuse. 2003;38:1109–31 ArticleGoogle Scholar
  22. Kumpfer KL, Fowler MA. Parenting skills and family support programs for drug-abusing mothers. Semin Fetal Neonatal Med. 2007;12:134–42 ArticleGoogle Scholar
  23. Bernardi E, Jones M, Tennant C. Quality of parenting in alcoholics and narcotic addicts. Br J Psychiatry. 1989;154:677–82.View ArticleGoogle Scholar
  24. Spieker SJ, Gillmore MR, Lewis SM, Morrison DM, Lohr MJ. Psychological distress and substance use by adolescent mothers: associations with parenting attitudes and the quality of mother-child interaction. J Psychoactive Drugs. 2001;33:83–93 ArticleGoogle Scholar
  25. Skinner ML, Haggerty KP, Fleming CB, Catalano RF, Gainey RR. Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships. J Addict Dis. 2011;30:17–26 ArticleGoogle Scholar
  26. Grella CE, Hser Y-I, Huang Y-C. Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services. Child Abuse Negl. 2006;30:55–73 ArticleGoogle Scholar
  27. Samaan Z, Bawor M, Dennis BB, Plater C, Varenbut M, Daiter J, Worster A, Marsh DC, Tan C, Desai D, Thabane L, Pare G. Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study. Neuropsychiatr Dis Treat. 2014;10:1503–8 ArticleGoogle Scholar
  28. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857–67.View ArticleGoogle Scholar
  29. Wilson Van Voorhis CR, Morgan BL. Understanding power and rules of thumb for determining sample sizes. Tutor Quant Methods Psychol. 2007;3:43–50 ArticleGoogle Scholar
  30. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495–9 ArticleGoogle Scholar
  31. McMahon TJ, Winkel JD, Suchman NE, Luthar SS. Drug dependence, parenting responsibilities, and treatment history: why doesn’t mom go for help? Drug Alcohol Depend. 2002;65:105–14.View ArticleGoogle Scholar
  32. Magura S, Nwakeze PC, Demsky SY. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 1998;93:51–60.View ArticleGoogle Scholar
  33. Kainu JP, Sarvela J, Tiippana E, Halmesmäki E, Korttila KT. Persistent pain after caesarean section and vaginal birth: a cohort study. Int J Obstet Anesth [Internet]. Churchill Livingstone; 2010 Jan 1 [cited 2019 Jan 12];19(1):4–9. Available from:
  34. Suchman NE, Luthar SS. Maternal addiction, child maladjustment and socio-demographic risks: implications for parenting behaviors. Addiction. 2000;95:1417–28.View ArticleGoogle Scholar
  35. Taplin S, Mattick RP. Mothers in methadone treatment and their involvement with the child protection system: a replication and extension study. Child Abuse Negl. 2013;37:500–10 ArticleGoogle Scholar
  36. Barth RP, Gibbons C, Guo S. Substance abuse treatment and the recurrence of maltreatment among caregivers with children living at home: a propensity score analysis. J Subst Abus Treat. 2006;30:93–104 ArticleGoogle Scholar
  37. Gregoire KA, Schultz DJ. Substance-abusing child welfare parents: treatment and child placement outcomes. Child Welfare. n.d.;80:433–52.Google Scholar
  38. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Can Fam Physician. 2011;57:e92–6.PubMedPubMed CentralGoogle Scholar
  39. McMahon TJ, Winkel JD, Luthar SS, Rounsaville BJ. Looking for poppa: parenting status of men versus women seeking drug abuse treatment. Am J Drug Alcohol Abuse. 2005;31:79–91.View ArticleGoogle Scholar
  40. McMahon TJ, Winkel JD, Rounsaville BJ. Drug abuse and responsible fathering: a comparative study of men enrolled in methadone maintenance treatment. Addiction. 2008;103:269–83 ArticleGoogle Scholar
  41. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006;82:211–7 ArticleGoogle Scholar
  42. Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007;102:616–22 ArticleGoogle Scholar
  43. Hudson TJ, Edlund MJ, Steffick DE, Tripathi SP, Sullivan MD. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manag. 2008;36:280–8 ArticleGoogle Scholar
  44. Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. J Consult Clin Psychol. 2014;82:448–59 ArticleGoogle Scholar


© The Author(s). 2019